Literature DB >> 31078505

Upregulation of eukaryotic translation initiation factor 3 subunit a promotes cell survival in ameloblastoma.

Zhenjiang Ding1, Jie Liu2, Junting Wang3, Biying Huang3, Ming Zhong4.   

Abstract

OBJECTIVES: This study aimed to detect the expression of eukaryotic translation initiation factor 3 subunit a (eIF3a) in ameloblastoma (AB) tissues compared with normal oral mucosa (NOM) tissues and investigate the roles of eIF3a in the immortalized ameloblastoma cell line (AM-1) cell proliferation and apoptosis. STUDY
DESIGN: We performed immunohistochemistry to determine the expression of eIF3a in AB tissues (n = 83) and NOM tissues (n = 20). Real time-quantitative polymerase chain reaction and Western blot analyses were conducted with AB tissues (n = 30) and NOM tissues (n = 6). The correlation between eIF3a expression and the clinical/pathologic features of patients with AB is also presented. The functional role of eIF3a in AM-1 cells was assessed with lentiviral vector-mediated shRNA (small hairpin RNA).
RESULTS: Our results indicated that eIF3a was significantly upregulated in AB. Additionally, eIF3a knockdown in AM-1 cells significantly inhibited cell proliferation and promoted apoptosis.
CONCLUSIONS: These data indicate that eIF3a facilitates the survival of AB cells and may serve as a promising therapeutic target in AB.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31078505     DOI: 10.1016/j.oooo.2019.02.016

Source DB:  PubMed          Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol


  2 in total

1.  A Retrospective Study of 158 Cases on the Risk Factors for Recurrence in Ameloblastoma.

Authors:  Ling Bi; Dong Wei; Dongsheng Hong; Jin Wang; Kejia Qian; Huiming Wang; Huiyong Zhu
Journal:  Int J Med Sci       Date:  2021-07-25       Impact factor: 3.738

2.  MicroRNA‑875‑5p inhibits tumor growth and metastasis of hepatocellular carcinoma by targeting eukaryotic translation initiation factor 3 subunit a.

Authors:  Tianxiang Chen; Liankang Sun; Bowen Yao; Liang Wang; Yufeng Wang; Yongshen Niu; Runkun Liu; Huanye Mo; Zhikui Liu; Kangsheng Tu; Qingguang Liu
Journal:  Oncol Rep       Date:  2020-08-19       Impact factor: 3.906

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.